ABBV - AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients | Benzinga
On Thursday, AbbVie Inc (NYSE:ABBV) released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients with folate receptor-alpha (FR?) positive, platinum-sensitive ovarian cancer (PSOC).
The study met its primary endpoint with an objective response rate (ORR) of 51.9%.
In addition, the median duration of response (DOR), a key secondary endpoint, was 8.25 months.
The safety profile of mirvetuximab soravtansine was consistent with previous studies’ findings, and ...